경피 흡수 패치 시장 보고서 : 유형, 유통 채널, 용도, 지역별(2024-2032년)

The global transdermal skin patches market size reached US$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.2 Billion by 2032, exhibiting a growth rate (CAGR) of 3.9% during 2024-2032.

Transdermal skin patches refer to a non-invasive and easy to use drug delivery method of administering constant and consistent therapeutic dosages into the bloodstream over a predetermined time. They consist of backings, drugs, membranes, adhesives, liners, chemical enhancers and permeators, physical aids, and low electrical current like iontophoresis. They provide a consistent diffusion rate, depending on the characteristics of the skin and the design of the patch. They are nowadays widely used as cosmetic, topical, and transdermal delivery systems around the world.

Transdermal Skin Patches Market Trends:

Transdermal skin patches are effective for treating cardiac and hormonal disorders, migraine, Parkinson's disease, Alzheimer's, stroke, human immunodeficiency virus (HIV), osteoporosis, and restless leg syndrome. Thus, a significant increase in the percentage of the population suffering from these ailments represents one of the key factors impelling the market growth. Moreover, these patches help avoid the traditional oral route for ingesting medicines, lower the inconvenience caused due to intravenous or parenteral therapies, and prevent gastrointestinal toxicity, nausea, and vomiting. Furthermore, due to the ease of administration, transdermal skin patches are gaining traction to improve the compliance of the patient during prolonged treatments for chronic pains and in smoking cessation therapy. Apart from this, the escalating demand for better therapeutics at affordable costs, coupled with a significant rise in the number of clinical trials of different drugs classes, is positively influencing the market. Furthermore, the introduction of pressure-sensitive adhesives and permeation enhancers, which lead to increased product diffusion and enhanced drug retention ability, is anticipated to provide lucrative opportunities to market players and expand the application of transdermal skin patches across the globe in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global transdermal skin patches market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, distribution channel and application.

Breakup by Type:

Single-layer Drug-in-Adhesive

Multi-layer Drug-in-Adhesive

Matrix

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Stores

Breakup by Application:

Pain Relief

Smoking Reduction and Cessation Aid

Overactive Bladder

Hormonal Therapy

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, AdhexPharma, LTS Lohmann Therapie-Systeme AG, Luye Pharma Group, Medherant Limited, Nitto Denko Corporation, Noven Pharmaceuticals Inc. (Hisamitsu Pharmaceutical Co. Inc.), Prosolus Inc., Samyang Holdings Corporation, Tapemark, Teikoku Pharma USA Inc. (Teikoku Seiyaku Co. Ltd), tesa SE (Beiersdorf AG) and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

• 1. What was the size of the global transdermal skin patches market in 2023?
• 2. What is the expected growth rate of the global transdermal skin patches market during 2024-2032?
• 3. What are the key factors driving the global transdermal skin patches market?
• 4. What has been the impact of COVID-19 on the global transdermal skin patches market?
• 5. What is the breakup of the global transdermal skin patches market based on the type?
• 6. What is the breakup of the global transdermal skin patches market based on the application?
• 7. What are the key regions in the global transdermal skin patches market?
• 8. Who are the key players/companies in the global transdermal skin patches market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Transdermal Skin Patches Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Single-layer Drug-in-Adhesive
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Multi-layer Drug-in-Adhesive
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Matrix
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacies
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Stores
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Pain Relief
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Smoking Reduction and Cessation Aid
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Overactive Bladder
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Hormonal Therapy
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 3M Company
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 AdhexPharma
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 LTS Lohmann Therapie-Systeme AG
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Luye Pharma Group
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Medherant Limited
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Nitto Denko Corporation
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Noven Pharmaceuticals Inc. (Hisamitsu Pharmaceutical Co. Inc.)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Prosolus Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Samyang Holdings Corporation
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Tapemark
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Teikoku Pharma USA Inc. (Teikoku Seiyaku Co. Ltd)
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 tesa SE (Beiersdorf AG)
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
  • 14.3.13 Teva Pharmaceutical Industries Ltd
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis